Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+1.79%
1,114.43
+19.60
+1.79%
—1,094.841,107.911,119.111,107.91——
SIXC
Communications
SIXC
Communications
SIXC
+1.62%
614.02
+9.81
+1.62%
—604.21604.21614.73604.21——
SIXE
Energy
SIXE
Energy
SIXE
-4.41%
1,194.62
-55.09
-4.41%
—1,249.711,219.461,219.461,191.66——
SIXI
Industrials
SIXI
Industrials
SIXI
+2.36%
1,780.39
+41.13
+2.36%
—1,739.261,754.111,783.961,754.11——
SIXM
Financials
SIXM
Financials
SIXM
+0.62%
639.55
+3.92
+0.62%
—635.63637.46643.42637.46——
SIXR
Staples
SIXR
Staples
SIXR
+0.27%
850.59
+2.27
+0.27%
—848.32850.90853.05846.68——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+1.56%
220.15
+3.39
+1.56%
—216.76216.76220.40216.76——
SIXT
Technology
SIXT
Technology
SIXT
+2.05%
3,403.38
+68.24
+2.05%
—3,335.143,376.133,406.123,360.29——
SIXU
Utilities
SIXU
Utilities
SIXU
-1.20%
928.09
-11.25
-1.20%
—939.34937.32937.59924.48——
SIXV
Health care
SIXV
Health care
SIXV
+0.12%
1,469.88
+1.71
+0.12%
—1,468.171,468.981,476.501,464.14——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+1.89%
2,432.11
+45.02
+1.89%
—2,387.092,394.182,432.012,394.18——
Q1 2026 earnings • released • EPS beat +143.25% • Revenue beat +5.35%
See results
ONC:NASDAQ
BeOne Medicines AG
$314.80
+5.82%
(+17.31) 1D
May 6, 2:22:21 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ONC...
Open
$306.49
High
$316.63
Low
$300.42
Mkt. cap
36.14B
Avg. vol.
199.74K
Volume
267.69K
52-wk high
$385.22
52-wk low
$219.16
Beta
0.50
Shares outstanding
118.57M
No. of employees
12K
News stories
From sources across the web
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market. BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024 the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Employees12K
FoundedOct 28, 2010
Headquarters-
SectorBiotechnology
Websitebeonemedicines.com
Last report
Just released
Today, 2:00 PM
Fiscal Period
Q1 2026
Normalized EPS / Estimate
1.96/ (0.81 est.)USD
+143.25%beat
Revenue / Estimate
1.51B/ (1.44B est.)USD
+5.35%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
1.12B
1.32B
1.41B
1.50B
Cost of goods sold
165.00M
164.61M
196.51M
142.42M
Cost of revenue
165.00M
164.61M
196.51M
142.42M
Research and development expenses
481.89M
524.90M
523.66M
615.42M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
459.29M
537.91M
529.00M
555.29M
Operating expense
941.18M
1.06B
1.05B
1.17B
Total operating expenses
1.11B
1.23B
1.25B
1.31B
Operating income
11.10M
87.88M
163.11M
185.04M
Other non operating income
19.38M
13.19M
-4.76M
4.16M
EBT including unusual items
20.90M
99.55M
147.16M
149.24M
EBT excluding unusual items
22.96M
102.67M
160.80M
189.96M
Income tax expense
19.63M
5.23M
22.32M
82.74M
Effective tax rate
93.92%
5.25%
15.17%
55.44%
Other operating expenses
-
-
-
-
Net income
1.27M
94.32M
124.84M
66.50M
Net profit margin
0.11%
7.17%
8.84%
4.44%
Earnings per share
-
0.84
1.09
0.58
Interest and investment income
12.85M
11.49M
13.79M
32.37M
Interest expense
-7.00M
-7.99M
-10.76M
-32.47M
Net interest expenses
5.85M
3.50M
3.03M
-103.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
42.73M
117.75M
198.86M
219.47M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer